A Phase II Study of AZD4877 (a Novel Anti-Mitotic Agent) in Advanced Bladder Cancer - Related Studies

A Phase II Study of AZD4877 (a Novel Anti-Mitotic Agent) in Advanced Bladder Cancer

This study is currently recruiting participants.

Study NCT00661609. Last updated on October 9, 2008. Information provided by AstraZeneca

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Bladder Cancer
		Transitional Cell Bladder Cancer
		Urethra Cancer
		Ureter Cancer
		Renal Pelvis Cancer

2	Additional conditions recognized in this trial
		Pelvic Neoplasms
		Ureteral Neoplasms
		Urethral Neoplasms
		Urinary Bladder Neoplasms

3	More general conditions related to this trial
		Neoplasms
		Neoplasms by Site
		Ureteral Diseases
		Urethral Diseases
		Urinary Bladder Diseases
		Urogenital Neoplasms
		Urologic Diseases
		Urologic Neoplasms

4	Interventions listed in this trial
		AZD4877

5	Sponsors listed in this trial
		AstraZeneca